Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today shared positive results from its Phase 1/2 ...

My name is Julianne, and I will be your conference facilitator today for Amgen's third quarter 2024 financial results ...

Looking ahead to 2025, We expect to read out the results of our pivotal AERIFY studies for itepekimab our IL-33 antibody in former ... cancer with more than 50% PD-L1 expression.

Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

The lock-and-load flexibility of the FHAB platform offers the bifunctional payload capability of adding another synergistic ...

The Society for Immunotherapy of Cancer (SITC) received over 1,500 abstract submissions in 2024, and has announced titles and authors for 42 accepted Late-Breaking Abstracts (LBA). New for 2024, all ...

Q3 2024 Earnings Call Transcript November 6, 2024 Coherus BioSciences, Inc. beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.1. Operator: Good day, and thank you for standing ...

Nektar said it is also planning "prudent" investment in IL-15 agonist candidate NKTR-255, in a mid-stage trial in bladder cancer alongside Merck KGaA's PD-L1 inhibitor Bavencio (avelumab), and ...

Epidermal growth factor receptor mutation and rearrangement of anaplastic lymphoma kinase were negative and the expression rate of programmed death - ligand 1 (PD-L1), a ligand for ... sclerosis and ...

This drug is an IL-6 inhibitor, which the company believes can do better than anti-FcRn inhibitors. Where this biotech fits in is the ability to be in a position to take what has been achieved ...

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses.